XML 70 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions, Divestitures, Research Collaborations and License Agreements - Acqusitions Narrative (Detail)
AUD / shares in Units, € in Millions, AUD in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2016
USD ($)
Jan. 21, 2015
USD ($)
Oct. 31, 2017
USD ($)
Oct. 31, 2017
EUR (€)
Jul. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jul. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jan. 31, 2016
USD ($)
Jul. 31, 2015
USD ($)
Feb. 28, 2015
USD ($)
renewal
Dec. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Feb. 28, 2018
AUD
AUD / shares
Feb. 28, 2018
USD ($)
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration $ 891,000,000                     $ 935,000,000 $ 935,000,000 $ 891,000,000 $ 590,000,000    
Goodwill $ 18,162,000,000                     18,284,000,000 18,284,000,000 18,162,000,000 17,723,000,000    
Discount rate (as percent) 11.50%                                
In-process research and development impairment charges                         483,000,000 3,600,000,000 63,000,000    
Changes in fair value                         (141,000,000) 407,000,000      
Agreement term                     2 years            
Payments to acquire business, net of cash acquired                         396,000,000 780,000,000 146,000,000    
Liability $ 8,514,000,000                     $ 11,117,000,000 11,117,000,000 8,514,000,000      
Amortization expense for intangible assets                         3,200,000,000 3,800,000,000 4,800,000,000    
Payments of contingent consideration                         100,000,000 25,000,000      
monoclonal antibody (cCAM)                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
In-process research and development impairment charges                           180,000,000      
Changes in fair value                           116,000,000      
uprifosbuvir                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
In-process research and development impairment charges                         $ 240,000,000 $ 2,900,000,000      
Rigontec                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Cash paid for acquisition of business     $ 140,000,000 € 119                          
Potential future milestone payments, maximum | €       349                          
Potential future milestone payment, research milestones and regulatory approvals | €       184                          
Potential future milestone payment, commercial targets | €       € 165                          
Afferent Pharmaceuticals                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Consideration transferred in business combination             $ 510,000,000                    
Cash paid for acquisition of business             487,000,000                    
Potential future milestone payments, maximum             750,000,000                    
Contingent consideration             223,000,000                    
In-process research and development (IPR&D)             832,000,000                    
Other net assets             29,000,000                    
Goodwill             $ 130,000,000                    
Discount rate (as percent)             11.50%                    
Deferred tax liabilities             $ 258,000,000                    
StayWell Company                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Cash paid for acquisition of business             150,000,000                    
Goodwill             275,000,000                    
Fair value of debt assumed in business combination             $ 150,000,000                    
Period before option becomes exercisable             3 years                    
Identifiable intangible assets             $ 238,000,000                    
Deferred tax liabilities             84,000,000                    
Other net liabilities             5,000,000                    
Noncontrolling interest             $ 124,000,000                    
Estimated useful life of intangible assets, acquired             10 years                    
Estimated useful life of intangible assets             5 years                    
Vallee SA                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Business Acquisition, Percentage of Voting Interests Acquired           93.50%           4.50% 4.50%        
Cash paid for acquisition of business           $ 358,000,000                      
Escrow Deposit           176,000,000                      
Other net assets           14,000,000                      
Goodwill           $ 171,000,000                      
Discount rate (as percent)           15.50%                      
Identifiable intangible assets           $ 291,000,000                      
Deferred tax liabilities           93,000,000                      
Noncontrolling interest           $ 25,000,000                      
Estimated useful life of intangible assets, acquired           15 years                      
Payments to Acquire Additional Interest in Subsidiaries                       $ 18,000,000          
Contingent liabilities           $ 37,000,000                      
Indemnification assets           $ 37,000,000                      
Moderna Therapeutics                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments               $ 200,000,000                  
IOmet Pharma Ltd                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Cash paid for acquisition of business                 $ 150,000,000                
Potential future milestone payments, maximum                 250,000,000                
Contingent consideration                 94,000,000                
In-process research and development (IPR&D)                 155,000,000                
Goodwill                 $ 57,000,000                
Discount rate (as percent)                 10.50%                
Deferred tax assets                 $ 32,000,000                
Payments of contingent consideration         $ 100,000,000                        
cCAM Biotherapeutics                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Cash paid for acquisition of business                   $ 96,000,000              
Contingent consideration                   105,000,000              
In-process research and development (IPR&D)                   180,000,000              
Goodwill                   14,000,000              
Other net noncurrent assets                   $ 7,000,000              
NGM Biopharmaceuticals                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments                     $ 94,000,000            
Cost Method Investment, ownership percentage                     15.00%            
Payments to acquire cost method investment                     $ 106,000,000            
Purchase commitment, maximum amount (up to)                     $ 250,000,000            
Agreement term                     5 years            
Revenue and cost allocation percentage (as percent) (up to)                     50.00%            
Number of extensions for research agreement | renewal                     2            
Cubist Pharmaceuticals Inc                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Consideration transferred in business combination   $ 8,300,000,000                              
Cash paid for acquisition of business   7,800,000,000                              
In-process research and development (IPR&D)   50,000,000                              
Other net assets   55,000,000                              
Goodwill   $ 4,670,000,000                              
Discount rate (as percent)   8.00%                              
Fair value of debt assumed in business combination   $ 1,900,000,000                              
Identifiable intangible assets   6,923,000,000                              
Deferred tax liabilities   2,519,000,000                              
Other net liabilities   $ 122,000,000                              
Estimated useful life of intangible assets, acquired   11 years                              
Transaction costs                             $ 324,000,000    
Other net noncurrent assets   $ 184,000,000                              
Cubist Pharmaceuticals Inc | Other noncurrent liabilities                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration   $ 50,000,000                              
Subsequent Event | Viralytics Limited [Member]                                  
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]                                  
Business acquisition, share price (in dollars per share) | AUD / shares                               AUD 1.75  
Future Payment That Will Be Made To Acquire Business                               AUD 502 $ 394,000,000